You are here: Home » News-CM » Companies » News
Business Standard

Natco Pharma launches HEPCINAT LP in Nepal

Capital Market 

Used in treatment chronic hepatitis C

Natco Pharma announced that it has launched the first licensed generic version of ledipasvir + sofosbuvir combination of Nepal, under its brand name Hepcinat LP.

Ledipasvir + Sofosbuvir is a two drug fixed-dose combination product that contains 90 mg of ledipasvir and 400 mg of sofosbuvir in a single tablet, and sold globally by Gilead Sciences Inc. under its brand HARVONI. It is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. NATCO priced generic medicine, Hepcinat LP, at an MRP of INR 25,000 for a bottle of 28 tablets in Nepal.

Powered by Capital Market - Live News

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, October 28 2015. 10:55 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU